Business Wire

Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
presented by
H
More Tools & Gadgets
F&G: 62
5.664,04 S&P · 21,93 Vola-Index · 103.720,01 BTC · 1,12506 EURUSD
Systemstatus: 42.537 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US28176E1082
Letzte Aktualisierung: 10.05.2025 | 12PM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG000BRXP69
EW
Edwards Lifesciences Corporation
GICS: - · Sektor: Healthcare · Sub-Sektor: Medical Devices
NAME
Edwards Lifesciences Corporation
ISIN
US28176E1082
TICKER
EW
MIC
XNYS
REUTERS
EW.N
BLOOMBERG
EW US
Di., 06.05.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today announced it will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, will participate in a fireside chat at 10:40 a.m. Pacific Time. A live webcast of the discussion will be available on...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Do., 01.05.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Approval of the SAPIEN 3 platfo...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mi., 23.04.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended Mar. 31, 2025. Recent Highlights Q1 sales grew 6.2% to $1.41 billion, or 7.9% adjusted1 Q1 TAVR sales grew 3.8%; constant currency1 sales grew 5.4%, better than expected Q1 TMTT sales grew 58% to $115 million with meaningful contribution to Edwards' growt...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Fr., 18.04.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly improved long-term outcomes compared to those receiving non-RESILIA tissue bioprosthetic valves. For more than 65 years, Edwards has been the leader in...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mi., 16.04.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2025 after the market closes on Wednesday April 23, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be ava...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 14.04.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation (MR) who are deemed unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy. Leveraging the...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 31.03.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today announced new scientific evidence presented and published during the American College of Cardiology’s (ACC) Annual Scientific Session & Expo, addressing the critical needs of patients with structural heart disease. Without treatment, 1 in 10 patients experiencing symptoms of severe aortic stenosis (AS) ma...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Di., 25.02.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025. Scott Ullem, chief financial officer, is scheduled to present at 9:50 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at ...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Di., 11.02.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024. Highlights and Outlook Q4 sales grew 9% to $1.39 billion1, better than expected, with strength across all product groups Q4 TAVR sales grew 6%; constant currency2 sales grew 5% Q4 TMTT sales grew 88% to $105 million with i...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Fr., 07.02.2025       Edwards Lifesciences
US28176E1082

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW). On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Di., 04.02.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2024 after the market closes on Tuesday February 11, 2025, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also b...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Sa., 25.01.2025       Edwards Lifesciences
US28176E1082

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Edwards Lifesciences Corporation (“the Company”) (NYSE: EW). On July 24, 2024, the Company announced its financial results for the second quarter of the Fiscal Y...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Di., 07.01.2025       Edwards Lifesciences
US28176E1082

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the J.P. Morgan Healthcare Conference on Tuesday, Jan. 14, 2025. Bernard Zovighian, chief executive officer, is scheduled to present at 11:15 a.m. PT. Scott Ullem, chief financial officer, will also participate in the conference. A live webcast of the presentation...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Do., 12.12.2024       Edwards Lifesciences
US28176E1082

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Edwards Lifesciences Corporation (“Edwards” or the “Company”) (NYSE: EW) and reminds investors of the December 13, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Do., 12.12.2024       Edwards Lifesciences
US28176E1082

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 13, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Edwards Lifesciences Corporation (“Edwards Lifesciences” or the “Company”) (NYSE: EW) securities between February 6, 2024 and July 24, 2024, inclusive (the “Clas...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mi., 11.12.2024       Edwards Lifesciences
US28176E1082

Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Edwards Lifesciences Corporation (NYSE: EW) between February 6, 2024 and July 24, 2024. Edwards describes itself as an “international company that researches, develops, provides products and tech...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mi., 04.12.2024       Edwards Lifesciences
US28176E1082

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, provide an update on its technology pipeline to serve more patients and share financial guidance today during its annual investor conference. Edwards enters 2025, its first full year as a purely structural heart company, in a s...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Di., 03.12.2024       Edwards Lifesciences
US28176E1082

The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation (“Edwards”) (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the “Class...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mo., 25.11.2024       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today announced one-year data highlighting the continued outstanding performance of its SAPIEN 3 Ultra RESILIA valve. The data were presented at PCR London Valves 2024 and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Interventions. An analysis of data from mo...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink
Mi., 30.10.2024       Edwards Lifesciences
US28176E1082

Edwards Lifesciences (NYSE: EW) today announced significant additions to the body of high-quality evidence presented and published during the Transcatheter Cardiovascular Therapeutics (TCT) conference, addressing the critical needs of patients with structural heart disease. “The data at TCT on Edwards’ innovations underscore our commitment to sci...
weiterlesen
Edwards Lifesciences
Research & Analysen Termsheet Terminal
Permalink

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.

Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds